Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 176 to 200 of 2422

TitleReference numberPublishedLast updated
Ranibizumab for treating diabetic macular oedemaTA274
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditionsIPG774
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Percutaneous deep venous arterialisation for chronic limb-threatening ischaemiaIPG773
Stroke rehabilitation in adultsNG236
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Virtual ward platform technologies for acute respiratory infectionsHTE13
Thyroid disease: assessment and managementNG145
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Urinary incontinence in neurological disease: assessment and managementCG148
Ovarian cancer: recognition and initial managementCG122
Suspected cancer: recognition and referralNG12
Suspected neurological conditions: recognition and referralNG127
Hearing loss in adults: assessment and managementNG98
Intrapartum careNG235

Results per page

  1. 10
  2. 25
  3. 50
  4. All